DE69633386D1 - Nukleinsäureliganden für gewebeziele - Google Patents

Nukleinsäureliganden für gewebeziele

Info

Publication number
DE69633386D1
DE69633386D1 DE69633386T DE69633386T DE69633386D1 DE 69633386 D1 DE69633386 D1 DE 69633386D1 DE 69633386 T DE69633386 T DE 69633386T DE 69633386 T DE69633386 T DE 69633386T DE 69633386 D1 DE69633386 D1 DE 69633386D1
Authority
DE
Germany
Prior art keywords
nucleic acid
tissue targets
acid ligands
cells
ligands
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69633386T
Other languages
English (en)
Other versions
DE69633386T2 (de
Inventor
Andrew Stephens
J Schneider
Larry Gold
Ulrich Speck
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Taisei Kako Co Ltd
Original Assignee
Schering AG
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/433,126 external-priority patent/US5688935A/en
Priority claimed from US08/433,124 external-priority patent/US5750342A/en
Application filed by Schering AG, Gilead Sciences Inc filed Critical Schering AG
Application granted granted Critical
Publication of DE69633386D1 publication Critical patent/DE69633386D1/de
Publication of DE69633386T2 publication Critical patent/DE69633386T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6811—Selection methods for production or design of target specific oligonucleotides or binding molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3517—Marker; Tag
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/10—Applications; Uses in screening processes
    • C12N2320/13—Applications; Uses in screening processes in a process of directed evolution, e.g. SELEX, acquiring a new function
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE69633386T 1995-05-03 1996-05-01 Nukleinsäureliganden für gewebeziele Expired - Lifetime DE69633386T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US433126 1995-05-03
US08/433,126 US5688935A (en) 1990-06-11 1995-05-03 Nucleic acid ligands of tissue target
US433124 1995-05-03
US08/433,124 US5750342A (en) 1990-06-11 1995-05-03 Nucleic acid ligands of tissue target
PCT/US1996/006059 WO1996034874A1 (en) 1995-05-03 1996-05-01 Nucleic acid ligands of tissue target

Publications (2)

Publication Number Publication Date
DE69633386D1 true DE69633386D1 (de) 2004-10-21
DE69633386T2 DE69633386T2 (de) 2005-09-22

Family

ID=27029755

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69633386T Expired - Lifetime DE69633386T2 (de) 1995-05-03 1996-05-01 Nukleinsäureliganden für gewebeziele
DE69637605T Expired - Lifetime DE69637605D1 (de) 1995-05-03 1996-05-01 Verfahren zur Identifizierung von Nukleinsäureliganden für Gewebsziele

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69637605T Expired - Lifetime DE69637605D1 (de) 1995-05-03 1996-05-01 Verfahren zur Identifizierung von Nukleinsäureliganden für Gewebsziele

Country Status (9)

Country Link
EP (3) EP0824540B1 (de)
JP (1) JPH11504812A (de)
AT (2) ATE276266T1 (de)
AU (1) AU727460B2 (de)
CA (2) CA2219106C (de)
DE (2) DE69633386T2 (de)
DK (1) DK1564290T3 (de)
ES (1) ES2310695T3 (de)
WO (1) WO1996034874A1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6346611B1 (en) * 1990-06-11 2002-02-12 Gilead Sciences, Inc. High affinity TGfβ nucleic acid ligands and inhibitors
US6716580B2 (en) 1990-06-11 2004-04-06 Somalogic, Inc. Method for the automated generation of nucleic acid ligands
US6127119A (en) * 1990-06-11 2000-10-03 Nexstar Pharmaceuticals, Inc. Nucleic acid ligands of tissue target
US6068829A (en) 1995-09-11 2000-05-30 The Burnham Institute Method of identifying molecules that home to a selected organ in vivo
US20070166741A1 (en) 1998-12-14 2007-07-19 Somalogic, Incorporated Multiplexed analyses of test samples
US6232287B1 (en) 1998-03-13 2001-05-15 The Burnham Institute Molecules that home to various selected organs or tissues
CA2360748A1 (en) * 1999-01-19 2000-07-27 Larry Gold Method and apparatus for the automated generation of nucleic acid ligands
US20040170955A1 (en) 2000-09-08 2004-09-02 Wadih Arap Human and mouse targeting peptides identified by phage display
US7420030B2 (en) 2000-09-08 2008-09-02 The Board Of Regents Of The University Of Texas System Aminopeptidase A (APA) targeting peptides for the treatment of cancer
US7452964B2 (en) 2001-09-07 2008-11-18 Board Of Regents, The University Of Texas System Compositions and methods of use of targeting peptides against placenta and adipose tissues
US8030465B2 (en) 2001-06-29 2011-10-04 Medimolecular Pty Ltd Nucleic acid ligands to complex targets
AU2775402A (en) * 2001-06-29 2003-01-02 Medimolecular Pty Ltd Nucleic acid ligands to complex targets
US7855054B2 (en) 2007-01-16 2010-12-21 Somalogic, Inc. Multiplexed analyses of test samples
US20110136099A1 (en) 2007-01-16 2011-06-09 Somalogic, Inc. Multiplexed Analyses of Test Samples
US8906700B2 (en) 2007-11-06 2014-12-09 Ambergen, Inc. Methods and compositions for phototransfer
EP2078751A1 (de) * 2008-01-11 2009-07-15 Commissariat A L'energie Atomique Spezifische zur Unterdrückung der Zellmigration und -invasion durch Krebszellen erzeugte Aptamere, Verfahren zur Auswahl derartiger Aptamere und ihre Verwendung
EP2159286A1 (de) * 2008-09-01 2010-03-03 Consiglio Nazionale Delle Ricerche Verfahren zur Gewinnung von Oligonucleotid-Aptameren und Verwendungen damit
AU2014353102B2 (en) 2013-11-21 2019-05-16 Somalogic Operating Co., Inc. Cytidine-5-carboxamide modified nucleotide compositions and methods related thereto

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5683867A (en) 1990-06-11 1997-11-04 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: blended SELEX
US5637459A (en) 1990-06-11 1997-06-10 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: chimeric selex
US5496938A (en) 1990-06-11 1996-03-05 Nexstar Pharmaceuticals, Inc. Nucleic acid ligands to HIV-RT and HIV-1 rev
JP2763958B2 (ja) 1990-06-11 1998-06-11 ネクスター ファーマスーティカルズ，インコーポレイテッド 核酸リガンド
US5270163A (en) 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
US5705337A (en) 1990-06-11 1998-01-06 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: chemi-SELEX
CA2104698A1 (en) * 1991-02-21 1992-08-22 John J. Toole Aptamers specific for biomolecules and methods of making
WO1992014842A1 (en) * 1991-02-21 1992-09-03 Gilead Sciences, Inc. Aptamers specific for thrombin and methods of use
US5726014A (en) * 1991-06-27 1998-03-10 Genelabs Technologies, Inc. Screening assay for the detection of DNA-binding molecules
WO1994029479A1 (en) * 1993-06-09 1994-12-22 Pharmagenics, Inc. Oligonucleotides which inhibit hiv protease function
DE69633227T2 (de) * 1995-05-03 2005-09-15 Gilead Sciences, Inc., Foster City Systematische evoultion von liganden durch exponentielle anreicherung: gewebe-selex
US20170110787A1 (en) 2015-10-14 2017-04-20 Apple Inc. Electronic Devices With Millimeter Wave Antennas And Metal Housings

Also Published As

Publication number Publication date
DE69633386T2 (de) 2005-09-22
ATE401424T1 (de) 2008-08-15
EP1564290A3 (de) 2006-02-01
AU5720096A (en) 1996-11-21
CA2641149A1 (en) 1996-11-07
ATE276266T1 (de) 2004-10-15
CA2219106C (en) 2008-09-23
EP0824540A1 (de) 1998-02-25
EP1564290B1 (de) 2008-07-16
EP0824540B1 (de) 2004-09-15
AU727460B2 (en) 2000-12-14
ES2310695T3 (es) 2009-01-16
DK1564290T3 (da) 2008-11-17
JPH11504812A (ja) 1999-05-11
WO1996034874A1 (en) 1996-11-07
EP0824540A4 (de) 2003-04-23
DE69637605D1 (de) 2008-08-28
CA2219106A1 (en) 1996-11-07
EP1564290A2 (de) 2005-08-17
EP2000534A3 (de) 2009-09-02
EP2000534A2 (de) 2008-12-10

Similar Documents

Publication Publication Date Title
DE69633386D1 (de) Nukleinsäureliganden für gewebeziele
CA2219807A1 (en) Systematic evolution of ligands by exponential enrichment: tissue selex
DE69434942D1 (de) Mehrzweckreagenzsystem zur schnellen lysierung von vollblutproben
ATE466960T1 (de) Verwendung von nukleinsäureliganden in der durchflusszytometrie
CA2002868A1 (en) Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
MX9100052A (es) Biblioteca(o conjunto)de bio-oligomeros al azar,un metodo de sintesis de los mismos y un metodo de uso de los mismos
ID28623A (id) Turunan 2-amino-tiazol, proses pembuatannya, dan penggunaannya sebagai zat anti tumor
ID28971A (id) Turunan 2-ureido-tiazol, proses pembuatannya, dan penggunaannya sebagai zat anti tumor
DE69940198D1 (de) Mikrovorrichtung zum screening von biomolekülen
DE68915258T2 (de) Verfahren zur katalytischen Oligomerisierung von Olefinen.
DE69533564D1 (de) Effektor-Proteine für Rapamycin
DE69903399D1 (de) Prepolymerisierte katalysatorkomponente für die polymerisierung von olefinen
WO1988007576A3 (fr) Proteines vasculaires anticoagulantes, leurs adn de codage, production et utilisation
ID21337A (id) Katalis terdorong, proses pembuatannya, dan penggunaannya dalam oksiklorinasi etilene
ATE355295T1 (de) Synthese von oligosacchariden, reagenzien und verfahren
DE69627414D1 (de) Zusammensetzung effektiv für die Entfernung von Asphalten
ATE179712T1 (de) Analoge für spezifische oligosaccharid-protein- wechselwirkungen und ihre verwendungen
DE69533876D1 (de) Zusammensetzung für die gentherapeutische Behandlung von Koronar-Arterienerkrankungen.
DE69008825D1 (de) Verfahren zur Reinigung von Phagen-DNA.
DE3789676D1 (de) Diagnostisches Verfahren für Gonorrhoe durch Proben von IgA1-Fragmenten.
CA2227491A1 (en) In situ preparation of nucleoside phosphoramidites and oligonucleotide synthesis
ID29565A (id) Terpolimer-terpolimer etilena dan proses pembuatannya
DE69002747T2 (de) Verfahren zur selektiven Hydrogenolyse von Perhalogenethanen.
FI873674A0 (fi) -2-plasmin-inhibitorliknande protein kodande dna.
DK0463043T3 (da) Fremgangsmåde til stabilisering af hybridiseringen af komplementære polynukleotidsekvenser

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: BAYER SCHERING PHARMA AG, 13353 BERLIN, DE

Owner name: TAISEI KAKO CO., LTD., OSAKA, JP

8327 Change in the person/name/address of the patent owner

Owner name: TAISEI KAKO CO., LTD., OSAKA, JP

Owner name: BAYER SCHERING PHARMA AKIENGESELLSCHAFT, 13353, DE